Further, the presence of mutations in RAS family oncogenes is associated with a lack of response to targeted therapy: lung and colorectal carcinomas characterized by KRAS mutations and KRAS and NRAS mutations, respectively are unresponsive to treatment with anti-EGFR agents [6, 11]. This evidence concerns the gene KRAS and colorectal carcinoma.